Administration Core

行政核心

基本信息

批准号：
10907198
负责人：
CLARE M TEMPANY
金额：
$ 35.54万
依托单位：
BRIGHAM AND WOMEN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-01-06 至 2025-12-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10907198
关键词：
Acute Advisory Committees Algorithms Articulation Attention Beds Biomedical Research Cancer Biology Clinical Collaborations Collection Communication Communities Consultations Data Data Set Dedications Development Devices Early Diagnosis Ensure Equipment Event Evolution Feedback Funding Generations Geographic Distribution Geography Goals Grant Group Meetings Guidelines Healthcare Heterogeneity Human Image Imaging Device Immunotherapy Information Retrieval Investigation Knowledge Leadership Lesion Malignant neoplasm of prostate Manuscripts Medical Mentors Mission Monitor Nanotechnology Neoplasm Metastasis Operative Surgical Procedures Participant Patient Care Patients Pattern Phase Policies Procedures Publications Recurrence Research Research Activity Research Design Research Personnel Resistance Resources Services Strategic Planning Structure Technology Testing Time Tissues United States National Institutes of Health Vision Work big-data science biomedical resource cancer care cancer heterogeneity cancer imaging care providers data curation data integration deep learning digital experience image guided image guided therapy imaging facilities imaging modality innovation interest meetings neoplastic new technology novel operation personalized cancer therapy personalized medicine precision medicine programs research study response shared decision making skills sound technology research and development tumor

项目摘要

The intersection of healthcare and biomedical research is at an inflection point with the convergence of cancer biology combined with new personalized therapies, the digital revolution, nanotechnology, big data science, and precision or personalized medicine. There is a wealth of meaningful information and knowledge that could be extracted from imaging data, but is currently not fully accessible by clinicians and hence cannot be optimally utilized for patient care, procedures or surgery. Medical care providers are constantly inundated with increasing amounts of patient data (both relevant and not) which are increasing in complexity. Cancer care exemplifies the current clinical challenges which include early detection, accurate distinction of pre-neoplastic and neoplastic lesions, determining infiltrative tumor margins during surgical treatment, tracking tumor evolution and potential acquired resistance to treatments over time, and prediction of tumor aggressiveness, metastasis pattern, and recurrence. Major strides have been made in the personalization of cancer therapies such as immunotherapy but the availability of specific, relevant, and timely medical data and information is of critical importance to realizing the full potential of precision medicine. Nowhere is this more acutely evident than during medical/surgical interventions in the operating and procedure rooms. Novel methods of imaging cancer to investigate the microstructure and inherent heterogeneity, image guidance, data integration, information extraction, and knowledge transfer are critical to inform and enable clinicians to fully leverage the information available, especially before, during and after invasive procedures. We are excited to propose this revised P41 biomedical resource center (BTRC) called Advanced Technologies for NCIGT or AT-NCIGT with 3 TRDs, 10 CP’s & 10 SPs. The 3 components, which we will investigate and develop new technology for are: Imaging Cancer heterogenity, Deep Learning and Intraoperative devices for image guided therapy. The BTRC will be organized with senior level experienced team led by the PI, assisted by TRD PI’s and others. They will support all research activities, ensure CP/SP support and review and mentor junior investigators and trainees. The overall goal of this proposal is to investigate, develop, and disseminate novel advanced technologies such as new MR sequences for tissue characterization-Imaging Cancer Heterogeneity (TR&D 1); analyze them and make them available through state-of-the- art algorithmic and data curation approaches (Deep Learning TR&D 2); and development of a set of comprehensive intraoperative planning, guidance and monitoring technologies and devices ( Intraoperative devices for image guided therapy TR&D 3). We will disseminate all innovations and specific deliverables to the CPs and SPs through the established mechanisms of the National Center for Image Guided Therapy (NCIGT), which continues to be dedicated to the investigation of the technical needs of IGT.

医疗保健和生物医学研究的交叉点正处于拐点，癌症生物学与新的个性化疗法、数字革命、纳米技术、大数据相结合科学、精准或个性化医疗有大量有意义的信息和信息。可以从成像数据中提取的知识，但目前还不能完全获取因此，医疗保健提供者无法最佳地用于患者护理、手术或手术。不断被越来越多的患者数据（相关和不相关）淹没癌症治疗的复杂性体现了当前的临床挑战，包括早期发现、准确区分肿瘤前病变和肿瘤病变，确定肿瘤浸润期间的边缘手术治疗，跟踪肿瘤演变和潜在的获得性治疗耐药性时间以及肿瘤侵袭性、转移模式和复发的预测取得了重大进展。癌症疗法（例如免疫疗法）的个性化已取得进展，但具体、相关、及时的医疗数据和信息对于实现全面的医疗数据和信息至关重要。精准医学的潜力在医学/外科手术中最为明显。在手术室和手术室中进行癌症成像的新方法来研究癌症的发生。微观结构和固有的异质性、图像引导、数据集成、信息提取和知识转移对于通知并使上级能够充分利用现有信息至关重要，特别是在侵入性手术之前、期间和之后，我们很高兴提出修订后的 P41。生物医学资源中心 (BTRC)，称为 Advanced Technologies for NCIGT 或 AT-NCIGT，具有 3 个 TRD， 10 个 CP 和 10 个 SP 我们将研究和开发新技术的 3 个组件是：用于图像引导治疗的癌症异质性成像、深度学习和术中设备。 BTRC 将由 PI 领导、TRD PI 和其他人将支持所有研究活动，确保 CP/SP 支持并审查和指导初级学生。该提案的总体目标是调查、制定和传播。新颖的先进技术，例如用于组织表征的新 MR 序列 - 癌症成像异质性（TR&D 1）；分析它们并通过最先进的算法使它们可用数据管理方法（深度学习 TR&D 2）和开发一套全面的方法；术中规划、引导和监测技术和设备（术中设备图像引导治疗 TR&D 3) 我们将向 CP 传播所有创新和具体成果。和 SP 通过国家影像引导治疗中心的既定机制（NCIGT），继续致力于 IGT 技术需求的调查。